Correale et al., showed that a higher level of FoxP3+ T-lymphocyte tumor infiltration in CRC patients receiving chemotherapy or chemo-immunotherapy was a favorable prognostic marker [27]. The gene discussed is FOXP3; the disease is colorectal carcinoma.